AZD 6738

Drug Profile

AZD 6738

Alternative Names: AZD6738

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer
  • Phase I/II Non-small cell lung cancer; Solid tumours
  • No development reported B cell lymphoma; Chronic lymphocytic leukaemia; Lymphoid leukaemia

Most Recent Events

  • 14 Nov 2017 AstraZeneca plans a phase II study in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in USA (NCT03330847)
  • 14 Nov 2017 AstraZeneca plans the phase II HUDSON trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA, Austria, Canada, Germany and South Korea, in November 2017 (NCT03334617)
  • 06 Nov 2017 Acerta Pharma plans a phase I/II trial for Chronic lymphocytic leukaemia (Monotherapy, Combination therapy, Second-line therapy or greater) in November 2017 (NCT03328273)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top